Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
Identifieur interne : 004346 ( Main/Exploration ); précédent : 004345; suivant : 004347Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
Auteurs : Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Rema Raman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-03.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Activities of Daily Living (classification), Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, Disease Progression, Double-Blind Method, Early, Female, Human, Humans, Male, Measurement scale, Middle Aged, Motor Skills (drug effects), Motricity, Neurologic Examination (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Placebo, Placebo Effect, Selegiline, Selegiline (adverse effects), Selegiline (therapeutic use), Tocopherol, Tocopherols (adverse effects), Tocopherols (therapeutic use), Treatment, UPDRS, placebo, placebo effects, rating scales.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Selegiline, Tocopherols.
- classification : Activities of Daily Living.
- diagnosis : Parkinson Disease.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Parkinson Disease.
- chemical , therapeutic use : Antiparkinson Agents, Selegiline, Tocopherols.
- Aged, Disease Progression, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebo Effect.
Abstract
The Unified Parkinson's Disease Rating Scale (UPDRS) is primarily composed of an investigator‐derived objective rating of motor function and a patient‐derived assessment of activities of daily living (ADL). Using a stringent definition of placebo effect, we examined the frequency, temporal development, and stability of improvements during placebo treatment over 6 months in a large placebo‐controlled trial of deprenyl and tocopherol in early Parkinson's disease (DATATOP). One hundred ninety‐nine subjects received placebo treatment in the randomized, multicenter, placebo‐controlled DATATOP study. We compared the baseline UPDRS motor section scores with follow‐up scores at 4, 13, and 26 weeks. Placebo‐associated improvement was defined as an improvement over baseline score in motor UPDRS of at least 50% or a change in at least two motor items at any one visit by two or more points. Seventeen percent of the 185 subjects who qualified for analysis met the placebo response criteria. The group prevalence of response was steady (7% to 10%) at any one visit without a marked predominance of an early study effect. Older subjects with more motor impairment at baseline were most likely to show a placebo‐associated improvement. ADL scores were low throughout the study, and ADL improvements did not identify the subjects with objectively defined placebo‐associated improvement. Prominent improvements in investigator‐derived objective measures of Parkinson's disease motor impairment occur during clinical trials, including one that was not aimed at showing improved short‐term efficacy. Although the notion of placebo effect often implies patient‐based perceptions, we found subjective changes to be infrequent in placebo‐treated patients, suggesting that either: (1) the placebo effect was rater‐driven; (2) the ADL questionnaire is insensitive to transient but objectively demonstrable motor changes; or (3) that the objective changes, albeit major, are within the realm of natural variation in the UPDRS motor scale from visit to visit. © 2002 Movement Disorder Society.
Url:
DOI: 10.1002/mds.10024
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B08
- to stream Istex, to step Curation: 000B08
- to stream Istex, to step Checkpoint: 002C37
- to stream Main, to step Merge: 006351
- to stream PascalFrancis, to step Corpus: 002795
- to stream PascalFrancis, to step Curation: 000526
- to stream PascalFrancis, to step Checkpoint: 002653
- to stream Main, to step Merge: 006692
- to stream PubMed, to step Corpus: 003B32
- to stream PubMed, to step Curation: 003B32
- to stream PubMed, to step Checkpoint: 003982
- to stream Ncbi, to step Merge: 000719
- to stream Ncbi, to step Curation: 000719
- to stream Ncbi, to step Checkpoint: 000719
- to stream Main, to step Merge: 006142
- to stream Main, to step Curation: 004346
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author><author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name></author><author><name sortKey="Raman, Rema" sort="Raman, Rema" uniqKey="Raman R" first="Rema" last="Raman">Rema Raman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AAF27C548FDE1A1C409C9C978DD5FBE28008C64D</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10024</idno><idno type="url">https://api.istex.fr/document/AAF27C548FDE1A1C409C9C978DD5FBE28008C64D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B08</idno><idno type="wicri:Area/Istex/Curation">000B08</idno><idno type="wicri:Area/Istex/Checkpoint">002C37</idno><idno type="wicri:doubleKey">0885-3185:2002:Goetz C:placebo:associated:improvements</idno><idno type="wicri:Area/Main/Merge">006351</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:02-0309306</idno><idno type="wicri:Area/PascalFrancis/Corpus">002795</idno><idno type="wicri:Area/PascalFrancis/Curation">000526</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002653</idno><idno type="wicri:doubleKey">0885-3185:2002:Goetz C:placebo:associated:improvements</idno><idno type="wicri:Area/Main/Merge">006692</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11921113</idno><idno type="wicri:Area/PubMed/Corpus">003B32</idno><idno type="wicri:Area/PubMed/Curation">003B32</idno><idno type="wicri:Area/PubMed/Checkpoint">003982</idno><idno type="wicri:Area/Ncbi/Merge">000719</idno><idno type="wicri:Area/Ncbi/Curation">000719</idno><idno type="wicri:Area/Ncbi/Checkpoint">000719</idno><idno type="wicri:doubleKey">0885-3185:2002:Goetz C:placebo:associated:improvements</idno><idno type="wicri:Area/Main/Merge">006142</idno><idno type="wicri:Area/Main/Curation">004346</idno><idno type="wicri:Area/Main/Exploration">004346</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences Rush University, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences Rush University, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Preventive Medicine, Rush University, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Raman, Rema" sort="Raman, Rema" uniqKey="Raman R" first="Rema" last="Raman">Rema Raman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Preventive Medicine, Rush University, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-03">2002-03</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="283">283</biblScope><biblScope unit="page" to="288">288</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AAF27C548FDE1A1C409C9C978DD5FBE28008C64D</idno><idno type="DOI">10.1002/mds.10024</idno><idno type="ArticleID">MDS10024</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living (classification)</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Early</term><term>Female</term><term>Human</term><term>Humans</term><term>Male</term><term>Measurement scale</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Motricity</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Placebo</term><term>Placebo Effect</term><term>Selegiline</term><term>Selegiline (adverse effects)</term><term>Selegiline (therapeutic use)</term><term>Tocopherol</term><term>Tocopherols (adverse effects)</term><term>Tocopherols (therapeutic use)</term><term>Treatment</term><term>UPDRS</term><term>placebo</term><term>placebo effects</term><term>rating scales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Selegiline</term><term>Tocopherols</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Selegiline</term><term>Tocopherols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Placebo Effect</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Echelle mesure</term><term>Homme</term><term>Motricité</term><term>Parkinson maladie</term><term>Placebo</term><term>Précoce</term><term>Sélégiline</term><term>Tocophérol</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Unified Parkinson's Disease Rating Scale (UPDRS) is primarily composed of an investigator‐derived objective rating of motor function and a patient‐derived assessment of activities of daily living (ADL). Using a stringent definition of placebo effect, we examined the frequency, temporal development, and stability of improvements during placebo treatment over 6 months in a large placebo‐controlled trial of deprenyl and tocopherol in early Parkinson's disease (DATATOP). One hundred ninety‐nine subjects received placebo treatment in the randomized, multicenter, placebo‐controlled DATATOP study. We compared the baseline UPDRS motor section scores with follow‐up scores at 4, 13, and 26 weeks. Placebo‐associated improvement was defined as an improvement over baseline score in motor UPDRS of at least 50% or a change in at least two motor items at any one visit by two or more points. Seventeen percent of the 185 subjects who qualified for analysis met the placebo response criteria. The group prevalence of response was steady (7% to 10%) at any one visit without a marked predominance of an early study effect. Older subjects with more motor impairment at baseline were most likely to show a placebo‐associated improvement. ADL scores were low throughout the study, and ADL improvements did not identify the subjects with objectively defined placebo‐associated improvement. Prominent improvements in investigator‐derived objective measures of Parkinson's disease motor impairment occur during clinical trials, including one that was not aimed at showing improved short‐term efficacy. Although the notion of placebo effect often implies patient‐based perceptions, we found subjective changes to be infrequent in placebo‐treated patients, suggesting that either: (1) the placebo effect was rater‐driven; (2) the ADL questionnaire is insensitive to transient but objectively demonstrable motor changes; or (3) that the objective changes, albeit major, are within the realm of natural variation in the UPDRS motor scale from visit to visit. © 2002 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></region><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name><name sortKey="Raman, Rema" sort="Raman, Rema" uniqKey="Raman R" first="Rema" last="Raman">Rema Raman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004346 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004346 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AAF27C548FDE1A1C409C9C978DD5FBE28008C64D
|texte= Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |